Last updated: August 9, 2026
1,3-Butylene glycol is a mature, nonexclusive pharmaceutical excipient used mainly as a solvent, humectant, viscosity modifier, and vehicle in topical and liquid formulations. Its pharmaceutical value is driven by supply reliability, purity, documentation, and regulatory acceptance rather than patent protection. Public companies generally do not disclose pharmaceutical-grade butylene glycol revenue separately, so the financial outlook is best assessed through volume growth, feedstock costs, qualification barriers, and substitution economics.
What is pharmaceutical-grade butylene glycol?
Pharmaceutical-grade butylene glycol normally refers to 1,3-butylene glycol, also known as 1,3-butanediol or CAS Registry Number 107-88-0. It should not be confused with 1,4-butanediol, CAS Registry Number 110-63-4, an industrial chemical with different toxicological and regulatory characteristics.
| Attribute |
1,3-Butylene glycol |
| Chemical name |
1,3-Butanediol |
| CAS number |
107-88-0 |
| Primary excipient functions |
Solvent, humectant, vehicle, viscosity modifier |
| Physical form |
Clear, colorless, viscous liquid |
| Main formulation use |
Topical, dermatological, cosmetic-pharmaceutical and selected liquid formulations |
| Pharmacopoeial relevance |
Used under applicable compendial and supplier specifications |
| Patent status |
Mature commodity; no meaningful product exclusivity |
| Principal commercial issue |
Consistent quality and qualified supply |
The excipient is miscible with water and compatible with many organic ingredients. It can improve feel, moisture retention, solubilization and preservation performance in topical products. Its role varies by formulation and concentration, and it is not an active pharmaceutical ingredient.
FDA’s Inactive Ingredient Database is the principal U.S. reference for inactive ingredients used in approved drug products. Product-specific acceptance still depends on route, dosage form, concentration and the regulatory filing in which the excipient is used [1].
How large is the pharmaceutical butylene glycol market?
No authoritative public source reports a separately audited market size for pharmaceutical-grade 1,3-butylene glycol. Industry market reports usually combine pharmaceutical, personal-care, cosmetics, food and industrial applications. That aggregation makes standalone pharmaceutical revenue estimates unreliable.
The pharmaceutical segment is likely smaller than cosmetics and personal care, where butylene glycol is widely used as a humectant, solvent and sensory modifier. Pharmaceutical demand is more defensible commercially because approved products tend to have long life cycles, but it grows more slowly than discretionary personal-care demand.
Market structure by application
| Application |
Relative demand position |
Commercial characteristics |
| Cosmetics and personal care |
High |
Broad use, rapid reformulation, strong demand for sensory and preservation benefits |
| Pharmaceuticals |
Moderate to low |
Lower volume, higher documentation and qualification requirements |
| Food and specialty formulations |
Variable |
Dependent on jurisdiction and permitted use |
| Industrial applications |
Variable |
More price-sensitive and less dependent on excipient documentation |
The pharmaceutical market is therefore a quality-premium niche within a larger commodity market. A supplier can obtain higher pricing for validated pharmaceutical material, but the premium is constrained by the availability of cosmetic and industrial alternatives.
What is driving demand for pharmaceutical butylene glycol?
Demand is supported by four factors.
First, liquid and topical drug development continues to favor multifunctional excipients that can combine solvent and humectant functions. A single excipient that supports solubility and product feel can simplify formulation design.
Second, dermatology and consumer-health products use vehicles that improve spreadability and water retention. Butylene glycol is relevant to creams, gels, lotions, solutions and other semi-solid or liquid dosage forms.
Third, manufacturers are seeking alternatives to ingredients that create sensory, toxicity, volatility or compatibility concerns. Butylene glycol may be selected over higher-volatility solvents or over propylene glycol when the target formulation requires a different skin feel.
Fourth, contract manufacturing and private-label pharmaceutical production expand the number of products using established excipient systems. This supports steady replacement demand even when new-drug launches are limited.
Demand is constrained by substitution. Formulators can often use propylene glycol, glycerin, polyethylene glycols, pentylene glycol, ethanol or other polyols, depending on dosage form and route.
How does butylene glycol compare with competing pharmaceutical excipients?
| Excipient |
Main advantages |
Main limitations versus 1,3-butylene glycol |
| Propylene glycol |
Low cost, extensive regulatory history, broad solvent utility |
Can produce more pronounced irritation or sensory effects in some topical products |
| Glycerin |
Strong humectancy, broad availability, established pharmaceutical use |
Higher viscosity and tack; may affect texture and processing |
| Polyethylene glycol |
Broad molecular-weight range and strong solubilization utility |
Different viscosity profile and possible formulation compatibility issues |
| Pentylene glycol |
Humectancy and antimicrobial-support properties |
Generally less commoditized and may carry a higher cost |
| Ethanol |
Volatile solvent, rapid drying, antimicrobial contribution |
Flammability, odor, evaporation and irritation concerns |
| 1,4-Butanediol |
Industrial chemical with different applications |
Not an interchangeable pharmaceutical excipient and should not be treated as 1,3-butylene glycol |
The most direct commercial comparison is with propylene glycol and glycerin. Butylene glycol tends to compete on formulation performance and patient or consumer acceptability rather than on absolute price.
What are the main cost and margin drivers?
The financial trajectory of butylene glycol is linked to feedstock economics, plant utilization and grade conversion costs.
Feedstock exposure
Commercial 1,3-butylene glycol production is linked to petrochemical and chemical-intermediate supply chains. Energy, acetaldehyde or related feedstock costs, transportation and regional capacity utilization affect producer margins. Bio-based routes may reduce fossil-feedstock exposure but can introduce higher raw-material, fermentation, purification and scale-up costs.
Purification and quality control
Pharmaceutical-grade material requires tighter controls over:
- Assay and water content
- Color and appearance
- Acidity or alkalinity
- Residual reaction intermediates
- Aldehydes and related impurities
- Elemental impurities
- Microbial quality where applicable
- Batch-to-batch consistency
- Packaging and traceability
The cost difference between industrial and pharmaceutical material is not limited to distillation or purification. It includes validated analytical methods, quality systems, documentation, stability data, change-control obligations, audits and regulatory support.
Contracting and qualification
Pharmaceutical customers usually qualify suppliers before commercial use. This process can take months or longer because it may require technical questionnaires, site audits, sample testing, stability work, quality agreements and regulatory filing updates.
Qualification creates customer retention and modest switching costs. It does not create durable exclusivity. A second supplier can usually be qualified if the formulation owner accepts the work and the new material performs equivalently.
What is the financial trajectory for butylene glycol suppliers?
The likely trajectory is steady volume growth with limited structural pricing power. Pharmaceutical-grade demand should expand in line with topical, dermatological, liquid and consumer-health formulations, but total market growth remains exposed to substitution and broader personal-care cycles.
| Financial variable |
Expected direction |
Rationale |
| Pharmaceutical-grade volume |
Gradual increase |
More topical and liquid formulations, plus replacement demand |
| Average selling price |
Stable to moderately volatile |
Feedstock and logistics movements; limited product differentiation |
| Gross margin |
Higher than industrial grade |
Documentation, qualification and quality-control premiums |
| Revenue visibility |
Moderate |
Approved products create recurring demand, but customers can dual-source |
| Pricing power |
Limited |
Multiple polyol substitutes and regional suppliers |
| Capital intensity |
Moderate to high |
Chemical production, purification, storage and quality infrastructure |
| M&A value |
Based on scale and customer qualification |
Standalone excipient assets are more attractive when integrated with broader portfolios |
Supplier revenue exposure is difficult to quantify because major chemical producers report broad business segments rather than pharmaceutical-grade butylene glycol. Public financial statements therefore cannot reliably isolate sales, EBITDA or market share for this excipient.
The strongest financial position belongs to suppliers that can sell across cosmetics, pharmaceuticals, food and specialty chemicals. Multi-market exposure improves plant utilization and reduces dependence on one regulatory channel. A producer serving only pharmaceutical customers may achieve a higher unit price but face lower volumes and greater customer-concentration risk.
What regulatory status does pharmaceutical butylene glycol have?
In the United States, butylene glycol may be used as an inactive ingredient in approved drug products subject to route, dosage form, concentration and product-specific regulatory review. The FDA Inactive Ingredient Database provides the relevant precedent framework, but it does not create blanket approval for every use or concentration [1].
In Europe, excipient use is governed through the medicinal-product authorization process, applicable European Pharmacopoeia requirements and excipient quality expectations. The European Commission’s excipient guideline requires appropriate assessment of excipient risk, quality, source and manufacturing controls [2].
Key regulatory requirements include:
- A defined material specification.
- Supplier qualification and audit rights.
- Impurity and residual-solvent controls.
- Change-notification procedures.
- Appropriate packaging and storage controls.
- Traceability to the manufacturing site.
- Supporting toxicological and compatibility information.
- Documentation suitable for the relevant drug master file or marketing authorization dossier.
Butylene glycol is not an active ingredient and does not require an ANDA-style approval by itself. Its acceptability is established through the drug product filing.
What patents protect pharmaceutical butylene glycol?
No meaningful product patent estate protects 1,3-butylene glycol as a pharmaceutical excipient. The compound is long-established, and any basic composition-of-matter protection would have expired decades ago.
Potentially relevant intellectual property can exist in:
- Manufacturing processes
- Bio-based production routes
- Catalyst systems
- Purification methods
- Specific pharmaceutical formulations
- Combination products
- Delivery systems using butylene glycol as one component
These rights would generally protect a process or finished product, not the ordinary purchase or use of commercially available 1,3-butylene glycol.
Orange Book and Paragraph IV status
Butylene glycol itself is not an Orange Book-listed drug product. It therefore has no standalone Orange Book patent listings, no standalone FDA pediatric exclusivity, and no Paragraph IV challenge pathway.
A Paragraph IV case could involve a finished drug product that contains butylene glycol, but the dispute would concern the active ingredient, formulation, method of treatment or drug-device combination. It would not ordinarily create exclusivity around the excipient.
What manufacturing and intellectual-property barriers exist?
The principal barriers are operational rather than legal.
A new supplier must demonstrate consistent impurity control, analytical equivalence, reliable production, acceptable packaging and regulatory support. Pharmaceutical customers may also require dual-site capability or documented business-continuity plans.
Manufacturing risks include:
- Feedstock interruptions
- Plant shutdowns
- Contamination or off-specification batches
- Changes in catalyst or purification operations
- Regional shipping constraints
- Packaging incompatibility
- Undeclared changes in manufacturing site or process
Intellectual-property risk is more relevant to novel bio-based production and low-carbon manufacturing routes. A supplier using a proprietary fermentation organism, engineered pathway or purification process could face licensing requirements or patent exposure. Buyers of conventional 1,3-butylene glycol generally face little IP risk from the ingredient itself.
Which companies compete in the butylene glycol supply chain?
Competition is fragmented across chemical producers, specialty-ingredient companies and regional distributors. Representative supply-side participants have included OQ Chemicals and KH Neochem, alongside regional manufacturers and distributors serving personal-care and pharmaceutical customers [3][4].
The competitive variables are:
- Manufacturing scale
- Regional inventory
- Pharmaceutical documentation
- Compendial compliance
- Ability to support audits
- Lot consistency
- Lead times
- Dual-source capability
- Bio-based or lower-carbon options
- Technical service
A supplier’s cosmetics business can be commercially important even when its pharmaceutical sales are modest. Personal-care demand can support production economics, while pharmaceutical customers provide more stable, qualified volume.
What generic-entry risks exist for drugs using butylene glycol?
Butylene glycol does not create a standalone generic-entry barrier. Generic manufacturers can normally source the excipient from qualified suppliers or use an alternative excipient if the formulation permits.
Risk can arise indirectly when:
- The originator owns a formulation patent that specifies a narrow excipient range.
- The excipient is essential to a difficult solubility or stability profile.
- A drug product has a device or delivery system that depends on the formulation.
- The ANDA applicant must demonstrate equivalence despite a complex topical or liquid formulation.
- The originator has method-of-use or formulation claims involving the complete product.
These risks belong to the finished pharmaceutical product. They do not materially increase the standalone value of butylene glycol.
How strong is the patent estate for pharmaceutical butylene glycol?
The patent estate is weak for the excipient itself and stronger only in selected manufacturing or finished-product contexts.
| IP category |
Protection outlook |
| 1,3-Butylene glycol composition |
Expired or unavailable as a practical exclusivity strategy |
| Pharmaceutical-grade specification |
Usually trade-secret, quality-system and know-how protection rather than patent exclusivity |
| Manufacturing process |
Potentially protectable, especially for bio-based or lower-cost routes |
| Formulation using butylene glycol |
Potentially patentable if the formulation has novelty and nonobvious performance |
| Finished drug product |
May carry active-ingredient, formulation or method-of-use patents |
| Supplier qualification |
Commercial switching barrier, not legal exclusivity |
What licensing deals and settlement agreements affect the market?
There are no widely recognized licensing deals or patent settlements that determine the market for conventional pharmaceutical-grade 1,3-butylene glycol. Licensing activity is more likely to arise around bio-based production technology, specialty formulations or proprietary delivery systems.
Because the ingredient is a mature input, commercial agreements typically involve supply, distribution, quality, territory, minimum volumes, price adjustment and change-control terms rather than patent settlement provisions.
Key Takeaways
- Pharmaceutical butylene glycol generally means 1,3-butylene glycol, CAS 107-88-0.
- The market is mature, fragmented and larger in cosmetics than in pharmaceuticals.
- Pharmaceutical demand should grow gradually, supported by topical, dermatological, liquid and consumer-health products.
- Public companies do not usually disclose pharmaceutical-grade butylene glycol revenue separately.
- Financial performance depends on feedstock costs, plant utilization, purification, documentation and customer qualification.
- The excipient has no meaningful standalone Orange Book, Paragraph IV or biosimilar exposure.
- Product patents are not the commercial protection mechanism. Process know-how, quality systems and qualified supply relationships matter more.
- Propylene glycol and glycerin are the principal practical substitutes.
- Manufacturing reliability and regulatory documentation are the main barriers to entry.
- The best-positioned suppliers combine pharmaceutical sales with cosmetics, food or industrial demand.
FAQs
Is butylene glycol the same as propylene glycol?
No. They are different glycols with different chemical structures and performance characteristics. Both can function as solvents or humectants, but they are not automatically interchangeable in a pharmaceutical formulation.
Can butylene glycol be used in injectable drugs?
Use in an injectable product would require route-specific regulatory support, safety assessment, quality controls and acceptance in the applicable drug filing. General availability as an excipient does not establish suitability for injection.
Does butylene glycol have an FDA monograph?
Regulatory acceptance may rely on inactive-ingredient precedent, supplier specifications and applicable compendial requirements. The FDA Inactive Ingredient Database is the principal U.S. reference for approved drug-product use [1].
Is bio-based butylene glycol commercially important?
Bio-based production can differentiate suppliers through renewable feedstocks and lower-carbon positioning. Its commercial success depends on cost, scale, impurity profile, lifecycle evidence and pharmaceutical customer qualification.
Can a drug manufacturer freely change its butylene glycol supplier?
No. A supplier change may require comparability testing, quality review, stability assessment and regulatory evaluation. The scope depends on the product, dosage form, regulatory jurisdiction and material specification.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
European Commission. (2015). Guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use. Official Journal of the European Union, C 95.
-
OQ Chemicals. (n.d.). Butylene glycol and specialty chemicals product information. https://www.oq.com
-
KH Neochem Co., Ltd. (n.d.). Specialty chemicals and 1,3-butylene glycol product information. https://www.khneochem.co.jp
